Literature DB >> 25252872

Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.

R A Abdelrahman1, K H Begna1, A Al-Kali1, W J Hogan1, M R Litzow1, A Tefferi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25252872     DOI： 10.1038/leu.2014.286

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Long-term outcome of treatment with ruxolitinib in myelofibrosis.

Authors:  Ayalew Tefferi; Mark R Litzow; Animesh Pardanani
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

2.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Authors:  Ayalew Tefferi; Francisco Cervantes; Ruben Mesa; Francesco Passamonti; Srdan Verstovsek; Alessandro M Vannucchi; Jason Gotlib; Brigitte Dupriez; Animesh Pardanani; Claire Harrison; Ronald Hoffman; Heinz Gisslinger; Nicolaus Kröger; Juergen Thiele; Tiziano Barbui; Giovanni Barosi
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

5.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

6.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Authors:  Naseema Gangat; Domenica Caramazza; Rakhee Vaidya; Geeta George; Kebede Begna; Susan Schwager; Daniel Van Dyke; Curtis Hanson; Wenting Wu; Animesh Pardanani; Francisco Cervantes; Francesco Passamonti; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

Review 7.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Authors:  Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

8.  Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Authors:  Animesh Pardanani; Jason R Gotlib; Catriona Jamieson; Jorge E Cortes; Moshe Talpaz; Richard M Stone; Michael H Silverman; D Gary Gilliland; Jolene Shorr; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

9.  Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  A Pardanani; R R Laborde; T L Lasho; C Finke; K Begna; A Al-Kali; W J Hogan; M R Litzow; A Leontovich; M Kowalski; A Tefferi
Journal:  Leukemia       Date:  2013-03-05       Impact factor: 11.528
  9 in total
  7 in total

1.  Myeloproliferative neoplasms and personalized medicine: the perfect match?

Authors:  Jean-Jacques Kiladjian; Claire Harrison
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

Review 2.  Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Omar Abdel-Wahab; Raajit Rampal; Ruben Mesa; Steffen Koschmieder; Ross Levine; Rüdiger Hehlmann; Giuseppe Saglio; Tiziano Barbui; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2016-05-31

3.  How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

Authors:  G Barosi; R P Gale
Journal:  Leukemia       Date:  2016-04-29       Impact factor: 11.528

4.  Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

Authors:  A Pardanani; J Gotlib; A W Roberts; M Wadleigh; S Sirhan; J Kawashima; J A Maltzman; L Shao; V Gupta; A Tefferi
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528

5.  Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.

Authors:  Susumu S Kobayashi; Shireen Vali; Ansu Kumar; Neeraj Singh; Taher Abbasi; Peter P Sayeski
Journal:  Oncotarget       Date:  2016-06-14

6.  Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.

Authors:  Cedric S Tremblay; Sung Kai Chiu; Jesslyn Saw; Hannah McCalmont; Veronique Litalien; Jacqueline Boyle; Stefan E Sonderegger; Ngoc Chau; Kathryn Evans; Loretta Cerruti; Jessica M Salmon; Adam McCluskey; Richard B Lock; Phillip J Robinson; Stephen M Jane; David J Curtis
Journal:  Nat Commun       Date:  2020-12-04       Impact factor: 14.919

Review 7.  The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.

Authors:  John O Mascarenhas; Srdan Verstovsek
Journal:  Cancer       Date:  2022-04-06       Impact factor: 6.921
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.